Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
21.68
+1.98 (10.05%)
At close: Dec 5, 2025, 4:00 PM EST
21.99
+0.31 (1.43%)
After-hours: Dec 5, 2025, 7:46 PM EST
Oculis Holding AG Employees
Oculis Holding AG had 49 employees as of December 31, 2024. The number of employees increased by 13 or 36.11% compared to the previous year.
Employees
49
Change (1Y)
13
Growth (1Y)
36.11%
Revenue / Employee
$20,245
Profits / Employee
-$2,664,287
Market Cap
1.25B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 49 | 13 | 36.11% |
| Dec 31, 2023 | 36 | 8 | 28.57% |
| Dec 31, 2022 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OCS News
- 2 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 25 days ago - Oculis Reports Q3 2025 Financial Results and Provides Company Update - GlobeNewsWire
- 4 weeks ago - Oculis to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 5 weeks ago - Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development - GlobeNewsWire
- 7 weeks ago - Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 - GlobeNewsWire
- 2 months ago - Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy - GlobeNewsWire
- 2 months ago - Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities - GlobeNewsWire
- 2 months ago - Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS - GlobeNewsWire